What's Hot
View all perspectives
Richard Conway
1 year ago
Fisher et al. In high disease activity, fatigue associates anxiety and synovial lining hyperplasia, 1.57[1.01,2.5]; p=0.047) In LDA, fatigue associates chronic lymphocytic synovial inflammation, 1.92[1.09,3.57]; p=0.024) Abstr#1630 #ACR23 @RheumNow https://t.co/Gev6pU3srq https://t.co/Ys8etP36ir
David Liew drdavidliew
1 year ago
Do we miss RA activity in obese pts?
Pre-clinical trial entry MSK USS:
similar DAS28
but lower SJC/US scores in obese
Is it because, in obese RA patients:
we underdetect on exam?
we undertreat?
higher risk, so lower penetrance of severe dx endotypes?
#ACR23 ABST1287 @RheumNow https://t.co/3FFPdBJOpz
Eric Dein
1 year ago
Vasculitis in SLE
A#1443 @RheumNow #ACR23
804 SLE pts, 74% black, 9.5% h/o vasculitis
45% visceral vasculitis, 43% cutanous, 8% both
Pts w vasculitis: younger age of SLE dx- 27 v 31y
Risks: other SARD, renal dx, neuro dx, low compl
Trend to higher mortality 21 to 14% (no signif)
Bella Mehta bella_mehta
1 year ago
Multimorbidity in #RA - VARA registry data- looking at 61 different biomarkers and 44 comorbidities
Chronic pain in 44%
Specific biomarkers seen in different morbidities
@rheumnow #ACR23 session#13M148 https://t.co/l6FU1ELKD3
Aurelie Najm
1 year ago
Peyton et al.: 4 multimorbidity patterns in RA
-Mental health and subst abuse
-Metabolic
-CV
-Chronic pain
All associated with different sets of biomarkers.
Some are very specific of one profile while others are widespread across profiles.
@RheumNow #ACR23 ABST1631 https://t.co/VqCrLI3oyy
David Liew drdavidliew
1 year ago
Ultrasound (and specifically intima-media thickness) might not just be for diagnosis in GCA - it might be a GCA disease activity measure for monitoring:
- improves over time
- increases with flares
Valentin Schaefer #ACR23 ABST1649 @RheumNow https://t.co/QWdIVGrHbn
Richard Conway
1 year ago
Ross et al. Ultrasound assessed Optic nerve sheath measurement in GCA. Previously shown increased in GCA. Here decreases with treatment shown in 9 patients Abstr#1650 #ACR23 @RheumNow https://t.co/fcrS4tT6U0 https://t.co/ylnPKzdUe0
Dr. Antoni Chan
1 year ago
In PS-matched study, no significant difference in respiratory hospitalisation or death between RA-ILD patients on non-TNFi/JAKi vs. TNFi. This finding does not support systematic avoidance of TNFi in RA-ILD, England B Abst#1582 #ACR23 #ACRBest @RheumNow https://t.co/1zVjMWNZZS https://t.co/d8TRIvGaIe
Eric Dein
1 year ago
Fate of ANA+/UCTD
A#1449 #ACR23 @RheumNow
207 asymptomatic ANA+ or UCTD followed
- <10% progress to SARD, 90% did not
Progression to SLE (11 pt), Sjo (5), SSc (3), RA (1)
Progressors to SLE: arthritis (91%), low compl (45%), alopecia (36%), ulcers (27%) - milder manifestations
TheDaoIndex KDAO2011
1 year ago
Abst#1583 SMART study: Split dose qwk MTX (10 mg QAM, 15 mg QPM) may have better efficacy compared to 25 mg single dose qwk MTX. RCT 253 RA patients: split dose had better DAS score, less likely to add other DMARDS, but slight⬆️in LFTs. #Plenary #ACR23 @rheumnow #ACRbest
Dr. John Cush RheumNow
1 year ago
Visit RheumNow's Booth at #ACR23
https://t.co/7HuNpWtf0M https://t.co/INtMGvEkA3
Richard Conway
1 year ago
Evidence of window of opportunity concept in PsA. Certainly >52 weeks delay associates with worse outcomes. <12 weeks and 12-52 weeks similar. Abstr#1641 #ACR23 @RheumNow https://t.co/fMb3D9zl8B https://t.co/rHu29Eflo0
Poster Hall